Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Homeolab USA Inc.
WARNING LETTER
•Homeolab USA Inc.•January 13, 2017

Homeolab USA Inc. – FDA Warning Letter, Jan 13, 2017

Record Details

The FDA issued a Warning Letter to Homeolab USA Inc. (part of Homeocan Inc.) following a January 9-13, 2017, inspection of their Montreal, Quebec drug manufacturing facility. The letter identifies significant violations of current Good Manufacturing Practice (CGMP) regulations (21 CFR, parts 210 and 211), rendering their drugs adulterated under section 501(a)(2)(B) of the FD&C Act.

Key violations include: 1. **Failure to validate manufacturing processes (21 CFR 211.110(a)):** The firm released multiple lots of homeopathic in-process powder blends, including those containing potentially toxic ingredients like belladonna for Infants' Teething Tablets, without validating the manufacturing process. FDA analyses of in-process and finished drugs showed non-homogeneous composition. The firm's subsequent validation attempt was deemed inadequate, lacking scientific justification for surrogate use, well-defined acceptance criteria, and an ongoing monitoring program. 2. **Failure to test components (21 CFR 211.84(d)(1) and (2)):** The firm did not perform adequate identity testing for components (e.g., belladonna) or validate test results for purity, strength, and quality. Relying on supplier Certificates of Analysis without adequate validation was cited.

The FDA also noted that a consultant impeded the inspection by preventing

Company
Homeolab USA Inc.
Inspection date
January 13, 2017
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Thomas J. Cosgrove
  • Matthew Schnupp
View Company Profile

ID · 855ecf0a-7744-4c50-99c4-7162a3bfc410

Violation Codes10
21 CFR 21021 CFR 21121 CFR 211.110(a)21 CFR 211.84(d)(1)21 CFR 211.84(d)(2)21 CFR 200.10(b)21 CFR 211.22(a)FD&C Act 501(a)(2)(B)FD&C Act 801(a)(3)21 U.S.C. 381(a)(3)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Homeolab USA Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.